跳至主要内容
临床试验/NCT01727037
NCT01727037Unknown2 期

A Feasibility and Safety Study of Bronchoscopic Intrabullous Autologous Blood Instillation for the Treatment of Severe Bullous Emphysema (BIABI Study)

Chelsea and Westminster NHS Foundation Trust6 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2012年10月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
发起方
入组人数
30
试验地点
6
主要终点
Change in the Residual Volume (RV) following treatment

研究概览

简要总结

Patients with large bullae (large empty air sacs in the lung) may benefit from bullectomy (surgery to resect these bullae), however this is a major surgery with significant potential morbidity and long hospital stays. Many patients are not well enough to have this surgery, or may not wish to have it. A less invasive means of attempting to shrink the size of the bullae is to directly inject the patients' own blood into the bullae (we believe that this can lead to an inflammatory reaction leading to gradual scarring and volume loss). This can be performed bronchoscopically in a 20-30 minute procedure using conscious sedation (avoiding general anaesthesia).

The aim of this study is to assess the effects on lung function, quality of life measures, functional measures and CT measured lung volumes of bronchoscopic intrabullous blood instillation in patients with bullous emphysema.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
35 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 35 years
  • Large bulla on CT scan where bullectomy is contraindicated or is actively avoided.
  • Hyperinflation - TLC ≥100% predicted, RV ≥150% predicted
  • Exertional breathlessness (mMRC >0)
  • Optimum COPD treatment for at least 6 weeks
  • No COPD exacerbation for at least 6 weeks
  • Fewer than 3 admissions for infective exacerbations in the preceding 12 months
  • Written informed consent

排除标准

  • Inability to obtain informed consent
  • Co-morbidities that would render bronchoscopy or sedation unsafe.
  • Anaemia or other reasons precluding venesection.
  • Clinically significant bronchiectasis
  • Arrhythmia or cardiovascular disease that poses a risk during procedure
  • Lung nodule requiring further investigation or treatment
  • Subject taking clopidogrel, warfarin, or other anticoagulants and unable to abstain for 5 days pre-procedure

研究组 & 干预措施

BIABI arm

Experimental

Patients will undergo intrabullous autologous blood instillation

干预措施: Bronchoscopic intrabullous autologous blood instillation (Procedure)

结局指标

主要结局

Change in the Residual Volume (RV) following treatment

时间窗: 6 months

次要结局

  • Change in RV/TLC ratio 6 months following treatment(6 months)
  • Change in the 6MWD 6 months following treatment(6 months)
  • Change in CT measured lung volumes 6 months following treatment(6 months)
  • Change in TLC 6 months following treatment(6 months)
  • Change in the intrathoracic gas volume 6 months following treatment(6 months)
  • Adverse events(6 monhts)
  • Changes in FEV1 and FVC 6 months following treatment(6 months)
  • Change in the SGRQ score 6 months following treatment(6 months)
  • Change in the mMRC score 6 months following treatment(6 months)
  • Change in DLCOc 6 months following treatment(6 months)

研究者

发起方
Chelsea and Westminster NHS Foundation Trust
申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Bronchoscopic Intrabullous Autologous Blood... | 临床试验